The Dermatology Digest

JANUARY 13, 2025

Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Dermatology Digest

JUNE 14, 2024

Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD.

Dermatitis 36

Dermatitis Marketing Innovations Safety 36

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. The most frequently reported TEAEs included nasopharyngitis, acne, upper respiratory tract infection, and atopic dermatitis.

Treatments 36

Treatments Dermatitis Pharmaceutical Eczema 36

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

MARCH 5, 2024

Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).

Injections 36

Injections Safety Sustainability Clinic 36

The Dermatology Digest

DECEMBER 18, 2023

New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Suggest the usage of crisaborole 2% ointment for mild to moderate atopic dermatitis. in a news release. “It

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36

The Dermatology Digest

DECEMBER 19, 2023

Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. The primary endpoint of the clinical trial was safety and tolerability. No patients experienced flare requiring rescue therapy.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

OCTOBER 24, 2024

APG777 continues to show promise in atopic dermatitis (AD), according to early data. APG777, in single doses up to 1,200mg or multiple doses of 300mg, showed a well-tolerated safety profile. Apogee Therapeutics, Inc. The company expects to report 16-week topline data from Part A of the trial in the second half of 2025.

Sustainability 36

Sustainability Dermatitis Safety Clinic 36

The Dermatology Digest

DECEMBER 16, 2024

When choosing a therapy for very young children living with AD, healthcare providers and caregivers have to account for unique considerations for pediatric patients, including sensitive skin, and select a medication that is appropriate for long-term use by a child with a chronic skin condition. Arcutis Biotherapeutics, Inc.

Safety 36

Safety Sensitive Skin Dermatitis Dermatology 36

The Dermatology Digest

OCTOBER 10, 2024

KT-621 is an investigational first-in-class once daily, oral STAT6 degrader with dupilumab-like activity in preclinical models and the potential to address multiple allergic and atopic diseases including atopic dermatitis, asthma, and chronic obstructive pulmonary disease, among others.

Clinic 36

Clinic Injections Dermatitis Safety 36

First Derm

DECEMBER 26, 2023

Dandruff (Seborrheic Dermatitis) Dandruff, medically known as seborrheic dermatitis , is a common scalp condition marked by excessive shedding of skin cells. Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a.

Management 49

Management Dermatitis Eczema Consultation 49

Aesthetics Advisor

MARCH 10, 2024

Randomized, double-blind, controlled trials suggest that excluding certain foods, such as eggs and chicken, can significantly improve atopic dermatitis. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Previously, I talked about the safety and efficacy of other, more natural treatments.

Eczema 36

Eczema Diet Dermatitis Document 36

The Dermatology Digest

JANUARY 9, 2024

The engineered bacterium has been validated in skin cell lines and its delivery has been validated in mice. “We have developed a topical therapy with a targeted approach, using what nature already has. acnes to address atopic dermatitis. We engineered a bacterium that lives in the skin and made it produce what our skin needs.

Sebum 36

Sebum Dermatitis Safety Technology 36

The Dermatology Digest

JANUARY 8, 2024

This study was a 16-week, Phase 2, randomized, double-blind, parallel group, placebo controlled, dose-ranging, multicenter study that evaluated the safety and efficacy of lutikizumab in 153 adult patients with moderate to severe HS who had previously failed anti-TNF therapy. Serious adverse events (SAEs) occurred in 5.3%

Medical 36

Medical Clinic Therapy Eczema 36

US Dermatologt Partners

SEPTEMBER 23, 2024

Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes. A dermatologist can provide treatments like: Laser therapy – lasers may be used around the eye area for a multitude of purposes. These treatments can be very effective but are not without risk.

Treatments 41

Treatments Chemical Peels Skincare Routine Sun Protection 41

Aesthetics Advisor

JUNE 16, 2024

As with so many skin-care trends that have come before, this one is rooted in medicine — in this case, regenerative medicine, which is centered on developing and applying therapies to help the body heal itself. But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.”

Aromatherapy 36

Aromatherapy Injections Ingredients Moisturization 36

US Dermatologt Partners

JANUARY 24, 2024

Multiple sclerosis (MS) –People with MS, especially those who receive disease-modifying therapies, are significantly more likely to develop psoriasis, according to research presented at the 2021 Consortium of Multiple Sclerosis Centers. Symptoms include abdominal cramping, changes in bowel movements, and blood in the stool.

Management 36

Management Skin Health Medical Dermatology 36

The Dermatology Digest

DECEMBER 13, 2024

Galderma) for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis. Food and Drug Administration (FDA) in August 2024.

Dermatitis 36

Dermatitis Safety Marketing Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Therapy Dermatitis Dermatology 36

The Dermatology Digest

DECEMBER 11, 2024

pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA )agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. AnaptysBio, Inc.is

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

AUGUST 13, 2024

Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis.

Dermatitis 36

Dermatitis Clinic Safety Dermatology 36

The Dermatology Digest

AUGUST 4, 2023

1 Explanations for the decline included poor compliance, poor reimbursement, fear of skin cancer, and the promise of newer therapies, said Dr. Richard. After at least 12 weeks of concomitant combination therapy, their facial vitiligo scores improved, and their total body vitiligo scores improved. It’s a great adjunct therapy.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

The Dermatology Digest

DECEMBER 5, 2024

Some of the key highlights related to atopic dermatitis (AD) therapies include: APG777 APG777 is a novel, subcutaneous, extended half-life monoclonal antibody (mAb) targeting interleukin (IL)-13. Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio.

Portfolios 74

Portfolios Dermatitis Sustainability Injections 74